| 1 | 18172273 | Phase I pharmacokinetic/pharmacodynamic study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor tyrosine kinase, in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in first-line treatment of patients with metastatic colorectal cancer. | Clin Cancer Res | 2008 Jan 1 |
1 |
| 2 | 18204257 | Advances in chemotherapy against advanced or metastatic colorectal cancer. | Digestion | 2008 |
1 |
| 3 | 18981587 | Association of ATP-binding cassette, sub-family C, number 2 (ABCC2) genotype with pharmacokinetics of irinotecan in Japanese patients with metastatic colorectal cancer treated with irinotecan plus infusional 5-fluorouracil/leucovorin (FOLFIRI). | Biol Pharm Bull | 2008 Nov |
1 |
| 4 | 19199273 | Carcinoembryonic antigen in monitoring of response to cetuximab plus FOLFIRI or FOLFOX-4 in patients with metastatic colorectal cancer. | Int J Biol Markers | 2008 Oct-Dec |
2 |
| 5 | 19364970 | Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan. | J Clin Oncol | 2009 May 20 |
2 |
| 6 | 20593498 | Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial. | World J Gastroenterol | 2010 Jul 7 |
1 |
| 7 | 20883737 | Dendritic cell vaccine in addition to FOLFIRI regimen improve antitumor effects through the inhibition of immunosuppressive cells in murine colorectal cancer model. | Vaccine | 2010 Nov 16 |
2 |
| 8 | 20921462 | Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. | J Clin Oncol | 2010 Nov 1 |
1 |
| 9 | 20948272 | [A case of high CEA colon cancer responding to neoadjuvant chemotherapy with FOLFIRI]. | Gan To Kagaku Ryoho | 2010 Oct |
1 |
| 10 | 20953860 | A phase I clinical trial of FOLFIRI in combination with the pan-cyclin-dependent kinase (CDK) inhibitor flavopiridol. | Cancer Chemother Pharmacol | 2010 Nov |
1 |
| 11 | 20954331 | [Current status and perspectives of biologics in the treatment of metastatic colorectal cancer]. | Nihon Rinsho | 2010 Oct |
1 |
| 12 | 21502544 | Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. | J Clin Oncol | 2011 May 20 |
4 |
| 13 | 21634054 | Efficacy of irinotecan in combination with 5-fluorouracil (FOLFIRI) for metastatic gastric or gastroesophageal junction adenocarcinomas (MGA) treatment. | Clin Res Hepatol Gastroenterol | 2011 Jan |
3 |
| 14 | 21635994 | Cost-effectiveness of targeted therapy with cetuximab in patients with K-ras wild-type colorectal cancer presenting with initially unresectable metastases limited to the liver in a German setting. | Clin Ther | 2011 Apr |
2 |
| 15 | 21669012 | Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer. | BMC Cancer | 2011 Jun 14 |
1 |
| 16 | 21773895 | Predictors of the efficacy of FOLFIRI plus bevacizumab as second-line treatment in metastatic colorectal cancer patients. | Surg Today | 2011 Aug |
1 |
| 17 | 21850381 | Genome-wide identification of possible methylation markers chemosensitive to targeted regimens in colorectal cancers. | J Cancer Res Clin Oncol | 2011 Oct |
3 |
| 18 | 21855038 | An open-label, single-arm, phase 2 trial of panitumumab plus FOLFIRI as second-line therapy in patients with metastatic colorectal cancer. | Clin Colorectal Cancer | 2011 Sep |
1 |
| 19 | 21868346 | [Efficacy of trsatuzumab (Herceptin) combined with FOLFIRI regimen in the treatment of HER2-positive advanced gastric cancer]. | Nan Fang Yi Ke Da Xue Xue Bao | 2011 Aug |
2 |
| 20 | 21989186 | Health-related quality of life in patients with metastatic colorectal cancer treated with panitumumab in first- or second-line treatment. | Br J Cancer | 2011 Nov 8 |
1 |
| 21 | 22044939 | Impact of SHMT1 polymorphism on the clinical outcome of patients with metastatic colorectal cancer treated with first-line FOLFIRI+bevacizumab. | Pharmacogenet Genomics | 2012 Jan |
1 |
| 22 | 22133572 | Response prediction in metastasised colorectal cancer using intratumoural thymidylate synthase: results of a randomised multicentre trial. | Eur J Cancer | 2012 Jul |
1 |
| 23 | 22192364 | Treatment decisions after diagnosis of metastatic colorectal cancer. | Clin Colorectal Cancer | 2012 Sep |
1 |
| 24 | 22199332 | Impact of chemotherapy for colorectal cancer on regulatory T-cells and tumor immunity. | Anticancer Res | 2011 Dec |
1 |
| 25 | 22201120 | Association of ABCC2 genotype with efficacy of first-line FOLFIRI in Japanese patients with advanced colorectal cancer. | Drug Metab Pharmacokinet | 2012 |
1 |
| 26 | 22269287 | Search for novel target molecules for the effective treatment or prevention of colorectal cancer. | Digestion | 2012 |
3 |
| 27 | 22554343 | Phase II study of combined chemotherapy with irinotecan and S-1 (IRIS) plus bevacizumab in patients with inoperable recurrent or advanced colorectal cancer. | Acta Oncol | 2012 Sep |
1 |
| 28 | 22934695 | UGT1A1 gene polymorphisms and the toxicities of FOLFIRI in Chinese Han patients with gastrointestinal cancer. | Anticancer Agents Med Chem | 2013 Feb |
1 |
| 29 | 22949147 | Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. | J Clin Oncol | 2012 Oct 1 |
1 |
| 30 | 23055389 | Cetuximab: a guide to its use in combination with FOLFIRI in the first-line treatment of metastatic colorectal cancer in the USA. | Mol Diagn Ther | 2012 Oct |
2 |
| 31 | 23507607 | [A case of locally advanced sigmoid colon cancer curatively resected after neoadjuvant chemotherapy with FOLFIRI plus panitumumab]. | Gan To Kagaku Ryoho | 2013 Mar |
1 |
| 32 | 23613396 | The role of K-RAS and B-RAF mutations as biomarkers in metastatic colorectal cancer. | J BUON | 2013 Jan-Mar |
2 |
| 33 | 23792567 | FOLFIRI plus dulanermin (rhApo2L/TRAIL) in a patient with BRAF-mutant metastatic colon cancer. | Cancer Biol Ther | 2013 Aug |
1 |
| 34 | 23792568 | Off-label use of cetuximab plus sorafenib and panitumumab plus regorafenib to personalize therapy for a patient with V600E BRAF-mutant metastatic colon cancer. | Cancer Biol Ther | 2013 Aug |
1 |
| 35 | 23861747 | Prospective validation of candidate SNPs of VEGF/VEGFR pathway in metastatic colorectal cancer patients treated with first-line FOLFIRI plus bevacizumab. | PLoS One | 2013 |
3 |
| 36 | 24018773 | Pharmacogenetics of ABC and SLC transporters in metastatic colorectal cancer patients receiving first-line FOLFIRI treatment. | Pharmacogenet Genomics | 2013 Oct |
1 |
| 37 | 24033692 | UGT1A1*6, 1A7*3, and 1A9*22 genotypes predict severe neutropenia in FOLFIRI-treated metastatic colorectal cancer in two prospective studies in Japan. | Cancer Sci | 2013 Dec |
1 |
| 38 | 24047539 | [Aflibercept (Zaltrap(®)) approved in metastatic colorectal cancer]. | Bull Cancer | 2013 Oct |
1 |
| 39 | 24231716 | [A case of hepatitis B virus reactivation in a patient with prior resolved hepatitis B infection during bevacizumab plus FOLFIRI treatment]. | Gan To Kagaku Ryoho | 2013 Nov |
1 |
| 40 | 24368879 | Ziv-aflibercept in metastatic colorectal cancer. | Biologics | 2014 |
1 |
| 41 | 24382596 | Pharmacokinetics, safety, and efficacy of FOLFIRI plus bevacizumab in Japanese colorectal cancer patients with UGT1A1 gene polymorphisms. | J Clin Pharmacol | 2014 May |
1 |
| 42 | 24462762 | Prognostic advantage of irinotecan dose escalation according to uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) genotyping in patients with metastatic colorectal cancer treated with bevacizumab combined with 5-fluorouracil/leucovorin with irinotecan in a first-line setting. | Transl Res | 2014 Aug |
1 |
| 43 | 24497922 | Genetic diversity of the KIR/HLA system and outcome of patients with metastatic colorectal cancer treated with chemotherapy. | PLoS One | 2014 |
2 |
| 44 | 24642571 | FOLFIRI combined with bevacizumab as first-line treatment for metastatic colorectal cancer patients with hyperbilirubinemia after UGT1A1 genotyping. | Med Princ Pract | 2014 |
2 |
| 45 | 24683007 | Biweekly cetuximab plus FOLFIRI/irinotecan as first/second-line chemotherapy for patients with KRAS wild-type metastatic colorectal cancer: a retrospective analysis in Southwest Chinese population. | Med Oncol | 2014 May |
1 |
| 46 | 24692733 | Multicenter phase II study of second-line cetuximab plus folinic acid/5-fluorouracil/irinotecan (FOLFIRI) in KRAS wild-type metastatic colorectal cancer: the FLIER study. | Anticancer Res | 2014 Apr |
1 |
| 47 | 24764659 | Role of cetuximab in first-line treatment of metastatic colorectal cancer. | World J Gastroenterol | 2014 Apr 21 |
1 |
| 48 | 24828248 | FcγR and EGFR polymorphisms as predictive markers of cetuximab efficacy in metastatic colorectal cancer. | Mol Diagn Ther | 2014 Oct |
2 |
| 49 | 24892446 | Prognostic significance of AMPK activation in advanced stage colorectal cancer treated with chemotherapy plus bevacizumab. | Br J Cancer | 2014 Jul 8 |
2 |
| 50 | 24942275 | Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next-generation sequencing: findings from the CAPRI-GOIM trial. | Ann Oncol | 2014 Sep |
2 |